

# Shih-Jer Hsu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2107193/publications.pdf>

Version: 2024-02-01

22  
papers

434  
citations

758635

12  
h-index

752256

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

807  
citing authors

#	ARTICLE	IF	CITATIONS
1	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	1.9	177
2	Micro-elimination of Chronic Hepatitis C by Universal Screening plus Direct Acting Antivirals for Incarcerated Persons in Taiwan. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa301.	0.4	27
3	Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 3-11.	0.8	19
4	Paradigm shift in the treatment options of hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2067-2079.	1.9	19
5	Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1187-1192.	0.8	18
6	Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions. <i>Journal of Medical Ultrasound</i> , 2019, 27, 81.	0.2	18
7	Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. <i>Hepatology International</i> , 2020, 14, 997-1008.	1.9	18
8	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	1.6	16
9	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE). <i>Open Forum Infectious Diseases</i> , 2019, 220, 557-566.	1.9	15
10	Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 956-964.	0.8	15
11	High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. <i>PLoS ONE</i> , 2017, 12, e0170028.	1.1	14
12	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	2.4	14
13	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. <i>Scientific Reports</i> , 2016, 6, 32303.	1.6	11
14	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	0.8	11
15	Direct comparison of biopsy techniques for hepatic malignancies. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 305-312.	4.5	11
16	A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 716-721.	0.8	8
17	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	1.9	6
18	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE, 2015, 10, e0137852.	1.1	5
20	Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. Viruses, 2021, 13, 2294.	1.5	4
21	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. Journal of the Formosan Medical Association, 2020, 119, 712-719.	0.8	3
22	Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy. Journal of the Formosan Medical Association, 2021, , .	0.8	0